James R Kasinger's most recent trade in CRISPR Therapeutics AG was a trade of 38,499 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2026 | 38,499 | 38,499 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2026 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 6,250 | 97,490 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2026 | 6,250 | 12,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 46.78 per share. | 20 Mar 2026 | 3,182 | 94,308 (0%) | 0% | 46.8 | 148,854 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 6,875 | 20,625 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2026 | 6,875 | 94,690 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 48.26 per share. | 14 Mar 2026 | 3,450 | 91,240 (0%) | 0% | 48.3 | 166,497 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 5,500 | 5,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 5,500 | 90,615 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 10 Mar 2026 | 2,800 | 87,815 (0%) | 0% | 52.8 | 147,840 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2025 | 2,114 | 2,113 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2025 | 2,114 | 84,478 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 66.60 per share. | 13 Oct 2025 | 1,076 | 83,402 (0%) | 0% | 66.6 | 71,662 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2025 | 16,500 | 16,500 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 84,914 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2025 | 6,250 | 18,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 41.23 per share. | 20 Mar 2025 | 3,185 | 81,729 (0%) | 0% | 41.2 | 131,318 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 36,666 | 36,666 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 27,500 | 27,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,500 | 11,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 5,500 | 80,380 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 42.42 per share. | 10 Mar 2025 | 2,850 | 77,530 (0%) | 0% | 42.4 | 120,897 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,250 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2025 | 2,250 | 79,780 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 43.32 per share. | 10 Mar 2025 | 1,116 | 78,664 (0%) | 0% | 43.3 | 48,345 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 20,000 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 20,000 | 82,597 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 53.85 per share. | 16 Feb 2025 | 9,595 | 73,002 (0%) | 0% | 53.9 | 516,691 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 3,825 | 3,825 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2025 | 3,825 | 76,827 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 52.80 per share. | 16 Feb 2025 | 1,947 | 74,880 (0%) | 0% | 52.8 | 102,802 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 30,000 | 30,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Oct 2024 | 18,333 | 18,333 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2024 | 2,113 | 4,227 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Oct 2024 | 2,113 | 63,686 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 13 Oct 2024 | 1,089 | 62,597 (0%) | 0% | 46.3 | 50,399 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 33,333 | 33,333 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Mar 2024 | 25,000 | 25,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,500 | 16,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 5,500 | 62,871 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 78.26 per share. | 10 Mar 2024 | 2,801 | 60,070 (0%) | 0% | 78.3 | 219,206 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,250 | 2,250 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2024 | 2,250 | 62,320 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 74.44 per share. | 10 Mar 2024 | 1,146 | 61,174 (0%) | 0% | 74.4 | 85,308 | Common Shares |
| CRISPR Therapeutics AG | Kasinger James R. | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 3,825 | 59,284 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2024 | 3,825 | 7,650 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | R. James Kasinger | General Counsel and Secretary | Sale of securities on an exchange or to another person at price $ 79.67 per share. | 18 Feb 2024 | 1,913 | 57,371 (0%) | 0% | 79.7 | 152,409 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2023 | 22,000 | 22,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,833 | 54,899 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,833 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,250 | 4,500 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,250 | 55,866 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.22 per share. | 10 Mar 2023 | 1,283 | 53,616 (0%) | 0% | 43.2 | 55,451 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 43.22 per share. | 10 Mar 2023 | 1,022 | 54,844 (0%) | 0% | 43.2 | 44,171 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 3,825 | 54,016 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2023 | 3,825 | 11,475 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.26 per share. | 18 Feb 2023 | 1,950 | 52,066 (0%) | 0% | 48.3 | 94,107 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2022 | 6,667 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2022 | 6,667 | 53,425 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.26 per share. | 03 Dec 2022 | 3,234 | 50,191 (0%) | 0% | 52.3 | 169,009 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2022 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 20,000 | 20,000 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,834 | 2,833 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,834 | 46,539 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,250 | 6,750 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 2,250 | 47,468 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.56 per share. | 10 Mar 2022 | 1,321 | 45,218 (0%) | 0% | 62.6 | 82,642 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.08 per share. | 10 Mar 2022 | 1,039 | 46,429 (0%) | 0% | 61.1 | 63,462 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 34,200 | 34,200 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2022 | 15,300 | 15,300 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 13,333 | 49,845 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Dec 2021 | 13,333 | 6,667 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 69.17 per share. | 03 Dec 2021 | 6,303 | 43,542 (0%) | 0% | 69.2 | 435,979 | Common Shares |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 10,800 | 10,800 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 10,000 | 33,911 (0%) | 0% | - | Common Shares | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Sale or transfer of securities back to the company at price $ 0.00 per share. | 10 Sep 2021 | 10,000 | 0 | - | - | Restricted Stock Units | |
| CRISPR Therapeutics AG | James R. Kasinger | General Counsel and Secretary | Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.86 per share. | 10 Sep 2021 | 4,741 | 29,170 (0%) | 0% | 117.9 | 558,774 | Common Shares |